"The U.S. Food and Drug Administration today approved TOBI Podhaler (tobramycin inhalation powder) for the management of cystic fibrosis
Cystic fibrosis is a genetic disease that affects about 30,000 pediatric and adult patients in the United "...
- Patient Information:
Details with Side Effects
Pulmozyme (dornase alfa) must be stored in the refrigerator at 2-8°C (36-46°F) and protected from strong light. It should be kept refrigerated during transport and should not be exposed to room temperatures for a total time of 24 hours. The solution should be discarded if it is cloudy or discolored. Pulmozyme (dornase alfa) contains no preservative and, once opened, the entire contents of the ampule must be used or discarded. Patients should be instructed in the proper use and maintenance of the nebulizer and compressor system used in its delivery.
Pulmozyme (dornase alfa) should not be diluted or mixed with other drugs in the nebulizer. Mixing of Pulmozyme (dornase alfa) with other drugs could lead to adverse physicochemical and/or functional changes in Pulmozyme (dornase alfa) or the admixed compound.
Last reviewed on RxList: 12/16/2008
This monograph has been modified to include the generic and brand name in many instances.
Additional Pulmozyme Information
Pulmozyme - User Reviews
Pulmozyme User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.